Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mon, 20 Nov 2017 21:15:00 +0000 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 923,085 additional shares of common stock. In addition, and in lieu of common stock, Mirati sold to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Mirati from this offering were approximately $92.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock Thu, 16 Nov 2017 13:45:00 +0000 SAN DIEGO, Nov. 16, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $80.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an additional 923,085 shares of common stock in connection with the public offering.
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock Wed, 15 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 15, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs Mon, 13 Nov 2017 21:15:00 +0000 SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today announced that it is reprioritizing its development programs to capitalize on encouraging data and development opportunities in its sitravatinib and KRAS programs. In addition, the Company announced that it has selected a clinical lead and backup compounds in its KRAS program that potently target KRAS G12C mutations.
Mirati reports 3Q loss Thu, 02 Nov 2017 09:49:49 +0000 The San Diego-based company said it had a loss of 65 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Mirati Therapeutics Reports Third Quarter 2017 Financial Results Wed, 01 Nov 2017 20:30:00 +0000 SAN DIEGO , Nov. 1, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the third quarter 2017. "We are excited ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 2.48 (median winner: 1.53)
Instit. Ownership: 65% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.